

## Salai Guggal-Boswellia Serrata Leukotriene Antagonist & Inhibitor: Clinical Applications

Inder Gupta, Annil Mahajan, Vijay Gupta

Inflammation is the hall mark of various diseases and is characterized by five symptoms; redness, heat, pain, swelling and decreased function. These symptoms are caused by a variety of inflammatory mediators which are listed in table 1.


So far only two major principles of antiphlogistic drug activity are available in therapy. First compounds inhibiting the synthesis of prostaglandin's by interfering with the cyclo-oxygenase system (salicylic acid, etc.). Second the gluco- corticosteroids, which finally inhibit both the cyclo-oxygenase pathway & the lipoxigenase pathway by interfering with the phospholipase. A2-reaction (Fig.1). However, there are number of inflammatory diseases where increased production of leukotrienes seems to be a reason for keeping the inflammatory process running. Among these diseases are: bronchial asthma, chronic inflammatory arthritis, hepatitis, psoriasis, ulcerative colitis and crohn's disease. In these diseases leukotriene antagonists are the target point as far as therapy is concerned. We briefly review the role of Salai Guggal as anti leukotriene and its applications in different diseases.

**Table. 1 Mediators of Inflammation**

Mediator	Origin	Appearance after	Inflammation symptoms
Bradykinin	Plasma	seconds	Vasodilatation, increased vascular permeability, pain
Histamine	Mast Cells	Seconds	Vasodilatation, increased vascular permeability, pain
Prostaglandins	Ubiquitous	Seconds	Vasodilatation, pain, sensitization against Bradykinin and histamine
Thromboxane	Thrombocytes other cells	Seconds	Platelet activation
Hydroxy-fatty acids	Ubiquitous	Seconds	Chemotactic for leucocytes, pain
Leucotrienes	Leucocytes	minutes	Chemotactic for leucocytes, increased vascular permeability
Lysosomal enzymes	Leucocytes synovial cells	minutes	Necrotic, chemotactic for leucocytes
Lymphokines	Lymphocytes	hours	Necrotic

From the Postgraduate Department of Medicine, Govt. Medical College Jammu (J&K).

Correspondence to : Dr. Inder Gupta, 81-Below Purani Mandi, Jammu (J&K) India.



**Fig. 1 Eicosanoid metabolic pathways**

Salai Guggal is a traditional remedy in Ayurvedic medicine used in India for a variety of inflammatory diseases including rheumatoid arthritis, osteoarthritis & cervical spondylosis. Salai guggal is the gumresin of *Boswellia serrata* Roxb. The main constituents of the gum resin are boswellic acids and other compounds such as volatile oils, terpinols, arabinosa, xylose, galactose, uronic acids,  $\beta$ -sisterin and phlobaphenes. Boswellic acids are also a constituent of the gum resin of *Boswellia carterti* Birdw, also known as Olibanum. The known pharmacological effects of Olibanum are anti-inflammatory, analgesic, immunosuppressive, hepatoprotective and antimicrobial (1,2). The gum resin of *Boswellia serrata* & *Boswellia carterti* is also widely used as incense for religious ceremonies. Salai guggal & boswellic acids have been shown to possess anti-inflammatory activity in a variety of animal's models (3-5).

### Boswellic Acids

The resin of *Boswellia serrata* is used in India for the treatment of chronic inflammatory arthritis. The raw product

is called 'salai guggal' when defatted ethanolic extracts of salai guggal was introduced into the 5 - lipoxygenase test system using calcium/calcium ionophore- stimulated peritoneal neutrophils of rats, it turned out that this extract significantly decreased production of  $LTB_4$  and total 5 - lipoxygenase products, the EC 50 being about 30  $\mu$ g/ml.

Boswellic acids are the main constituents of the ethanolic extract of the resin of *Boswellia serrata*. Different Boswellic acids have been identified including  $\beta$ -Boswellic acid,  $\alpha$ -Boswellic acid and 11-keto- $\beta$ -Boswellic acid and other acetyl forms (9-13).

Crude ethanolic extracts of the resin and or Boswellic acid have pharmacological actions as anti-inflammatory, inhibition of complement system and hepatoprotective. Studies of the boswellic acids possible effects on cyclooxygenase or 12- lipoxygenase activity showed that they affected neither prostaglandin synthesis nor 12- lipoxygenase activity suggesting that this type of pentacyclic triterpenes may inhibit only leukotriene

synthesis. Boswellic acids are specifically non-redox inhibitors of 5-lipoxygenase (14-23).

### Clinical Applications

#### Rheumatoid Arthritis & Osteoarthritis:

In the traditional Ayurvedic medicine of India the use of Salai guggal is very common to treat inflammatory disease including chronic polyarthritis especially rheumatoid arthritis and osteoarthritis. Many preparations like S-compound Sallaki, H15 etc. are available in the market for the treatment of these inflammatory and degenerative diseases (24-28).

#### Inflammatory Bowel Diseases

a. Ulcerative colitis is a chronic inflammatory disease with remissions and exacerbations affecting principally the rectal mucosa, the left colon but in many instances the entire colon. It is characterized by rectal bleeding and diarrhea appearing principally.

Though the aetiology of this disease is complex, it has been reported that the inflammatory process is associated with extensive leukocyte infiltration & increased formation of leukotrienes. Drug therapy so far is mainly limited to the use of sulfasalazine or other aminosalicylates and corticosteroids but they are weak inhibitors of leukotrienes production & cellular interleukin-1 release and dose dependent modifiers of prostaglandin profile, all of which might affect the inflammatory response in inflammatory bowel diseases.

Boswellia serrata blocked leukotriene biosynthesis in neutrophilic granulocytes, being direct non-redox and non-competitive inhibitors of 5-lipoxygenase - Gupta *et al.* (29) have for the first time demonstrated the use of Boswellia serrata in ulcerative colitis.

b. Crohns Disease is also a chronic inflammatory disease with remission and exacerbations. Leukotrienes ( $LTB_4$ ) are major chemotactic factors in such patients and large amounts of leukotrienes are found in the mucosa of patients with Crohns disease. Gerhardt *et al* (30) had confirmed in their studies that therapy with Boswellia serrata is not inferior to mesalazine in Crohns disease. Considering

both safety and efficacy of Boswellia serrata extract it appears to be superior over mesalazine in terms of a benefit risk evaluation.

#### Bronchial Asthma

It is a chronic inflammatory condition characterized by bronchial hyperresponsiveness and reversible airway obstruction. A wide range of compounds mediate these processes. Leukotrienes were identified as products of arachidonic acid metabolism and as inflammatory mediators in the late 1970. Prior to this their existence was recognized as the slow-reacting substances of anaphylaxis (SRS-A) a term coined by Feldberg and Kellaway in 1938. In 1940, Kellaway and Trethewie suggested a role of SRS-A in asthma but it was not until 40 years later that it became clear that SRS-A consisted of the leukotrienes. Besides causing chemotaxis, chemokinesis, synthesis of superoxide radicals and release of lysosomal enzymes by phagocytes leukotrienes cause (a) broncho-constriction (b) mucosal oedema (c) increased mucus secretion and (d) an inflammatory cellular infiltrate rich in eosinophils (31-41).

Anti-leukotriene drugs either inhibit the synthesis of leukotrienes from arachidonic acid (e.g. zileuton, MK-886, BAYX1005) or act as leukotriene receptor antagonists (e.g. zafirlukast, ICI 204, 219; montelukast, MK0476, pranlukast, iralukast). The gum resin of Boswellia serrata (salai guggal) was shown to block leukotrienes biosynthesis due to the action of genuine boswellic acids constituents. Keto-boswellic acid (i.e. AKBA-acetyl: II-Keto- $\beta$ -Boswellic acid) are orally, active direct non-redox and noncompetitive inhibitors of 5-lipoxygenase (19).

Gupta *et al.* (36) have shown that Boswellia serrata induces remission in patients with bronchial asthma. Improvement of the disease is evident by disappearance of physical symptoms and increase in FEV1, FVC and PEFR as well as decrease in eosinophilic count and ESR.

#### Peritumoral Brain Oedema

Boswellia serrata containing AKBA and KBA provided promising result in reducing peritumoral brain oedema in patients with malignant glioblastomas along with a decreased

urinary leukotriene excretion. Heldt *et. al.* have shown cysteinyl leukotrienes as potential mediators of the peritumoral brain oedema in astrocytoma patients while Boker *et. al.* reported wonderful effects in therapy of malignant glioma. Higher dose of drugs in grams are given in reducing intracranial pressure in head injuries (42-45).

### Psoriasis

Psoriasis is another disease characterized by extensive leukocyte infiltration albeit into the skin rather than the rectal mucosa. Measurements have been made for the presence of various chemotactic agents in psoriatic lesions and the presence of LTB<sub>4</sub> like immunoreactive material has been described. There have also been suggestions that existing drugs may act by inhibiting the production of leukotrienes. Clinical trials have been carried out with both zileuton (topically and systematically) and MK-886. These agents were found not to decrease the amount of LTB<sub>4</sub> like material found in psoriatic skin lesions indicating that this material is not derived through the action of the 5-lipoxygenase pathways(46). Many studies are showing good results of boswellic acids in the treatment of psoriasis(47).

### Chronic Colitis

Chronic nonspecific colitis is a common disease characterized by vague lower abdominal pain bleeding per rectum with diarrhea and palpable tender descending as well as sigmoid colon (48-50). This disease is seen in young and middle aged persons and may be a variation of ulcerative colitis. Gupta *et. al.* (24) have shown promising results with *Boswellia serrata* in chronic colitis.

### Glomerulonephritis

Leukotrienes mediate the alterations in renal haemodynamic and glomerular filtration, which occur in a variety of nephritis including nephrotoxic serum nephritis, murine lupus and passive Heyman nephritis. A correlation between neutrophil infiltration and glomerular LTB<sub>4</sub> synthesis has been defined. Cysteinyl leukotrienes play a role in the pathogenesis and progression of glomerulonephritis not only through effects on renal blood flow and filtration but also through proliferative changes in response to both LTC<sub>4</sub> and LTD<sub>4</sub> and in vivo inhibition of LT biosynthesis in nephritic rats with MK-886 by preventing glomerular cell proliferation

(11). Many studies are underway which show that gum resin of *Boswellia serrata* is very effective in nephritis patients(47).

### Other Diseases

Animal studies have shown that *Boswellia serrata* is effective in treatment of drug induced hepatitis and lupoid hepatitis. Clinical trials are being conducted for the effects of Boswellic acid in these diseases(50,51).

### References

1. Kar A, Menon MK. Analgesic effect of the gum resin of *Boswellia serrata* Roxb. *Life Sci* 1969;8:1023-28.
2. Wagner H, Knaus W, Jordan E. Pflanzin hallsstoffe Wirkung auf das Komplement system. *Z Phytotherapie* 1987; 8 148-49.
3. Singh GB, Atal CK Pharmacology of an extract of salai guggal, ex- *Boswellia serrata*, a new non-steroidal anti inflammatory agent. *Agents Actions* 1986; 18: 407-12.
4. Sharma ML, Bani S, Singh GB. Anti arthritic activity of boswellic acids in bovine serum albumin (BSA) induced arthritis. *Int J Immuno-pharmacological* 1989;11: 647-52.
5. Sajayhi H, Mack T, Ammon HPT. Protection by boswellic acids against galactosamine/endotoxin induced hepatitis in mice. *Biochem Pharmacol* 1991;41:1536-37.
6. Bray MA, Cunningham FM, Ford Hutchinson AW, Smith MJH. Leukotriene B<sub>4</sub>: A mediator of vascular permeability. *Br J Pharmacol* 1981;72: 483-86.
7. Budzimekiewicz H, Wilson JM, Dyrassi C. Mass spectrometry in structural and stereochemical problems XXXII. pentacyclic triterpenes. *J Am Chem Soc* 1963; 85: 3688-99.
8. Dixon RAF, Diehl RE, Opas E, Rands E, Vickers P *et al.* Requirement of a 5 -lipoxygenase activating protein for leukotriene synthesis. *Nature(Lond)* 1990;343: 282-84.
9. Ford Hutchinson AW, Bray MA, DOIG, MV, Shibly ME & Smith MJH. Leukotriene B<sub>4</sub>, a potent chemokinetic and aggregating substance released from poly-morphonuclear leukocytes. *Nature(Lond)* 1980;286: 264 -65.
10. Hammarstrom S. Leukotrienes. *Annu Rev Biochem* 1983; 52, 355-77.
11. Pardhy, RS, Bhalta charyya SC. Beta-Boswellic Acid, acetyl β-boswellic acid, acetyl-11-keto, β-Boswellic acid four pentacyclic triterpene acids from the resin of *Boswellia serrata* Roxb. *Ind J Chem* 1978; 16B 176 -178.
12. Piper PJ. Formation and actions of Leukotrienes. *Physiol Rev* 1984; 64: 744-61.
13. Samuelsson B. Leukotrienes. Mediators of immediate hypersensitivity, reaction of inflammation. *Science (Wash DC)* 1983; 220: 568-75.
14. Sharon P, Stenson WF: Enhanced synthesis of leukotrienes B<sub>4</sub> by colonic mucosa in inflammatory bowel disease. *Gastroenterology* 1984; 86. 453-60.
15. Lewis RA, Austen KF. The biologically active leukotrienes. Biosynthesis, metabolism, receptors functions and pharmacology. *J Clin Invest* 1984;75:889-97.

16. Hawkey CJ, Lacoστο M. Inhibition of prostaglandin synthetase in human rectal mucosa. *Gut* 1983;24: 213-17.
17. Green field SM, Punchard NA, Teare JP, Thompsan RP. The mode of action of the aminosalicylate in inflammatory bowel disease. *Aliment Pharmacol Therapeutics* 1993;7: 369-83.
18. Ammon HPT, Mack T, Singh GB, Safayhi H. Inhibition of LTB<sub>2</sub> formation in rat peritoneal neutrophils by an ethanolic extract of the gum resin extract of boswellia serrata. *Planta Med.* 1991; 57: 203-07.
19. Safayhi H, Sailer ER, Ammon HPT. Mechanism of 5-lipoxygenase inhibitions by acetyl-II-keto-β-boswellic acid. *Mol Pharmacol* 1995;47: 1212-1216.
20. Safayhi H, Mack T, Sabieray J, Anazodo MI, Subramanian IR, Ammon HPT. Boswellic acid noval specific non-redox inhibitors of 5- lipoxygenase. *J Pharmacol Exp Ther* 1992; 261: 1143-46.
21. Hawthorne AB, Boughton Smith NK Whittle BJ, Hawkey CJ. Colorectal Leukotrienes B<sub>4</sub> synthesis in vitro inflammatory bowel disease. Inhibition by the selective 5-lipoxygenase inhibitor, BWAYC. *Gut* 1992; 33: 513-17.
22. Wallac JL, Keenam CM. Orally active inhibitors of leukotriene synthesis accelerates healing in a rat model of colitis. *Am J physiol* 1990; 258,G 527- G534.
23. Laurson LS, Naesdal J, Bukhave K, Lauritsen K, Rask - Madsen J. Selective 5-lipoxygenase inhibition in ulcerative colitis. *Lancet* 1990; 335. 683-85.
24. Gupta I, Parihar A, Malhotra P, et al. Effects of gum resin of Boswellia serrata in patients with chronic colitis. *Planta Medica* 2001; 67:391-95.
25. Ammon HPT, Salai Guggal - Boswellia Serrata; From a herbal medicine to a non- redox inhibitor of leukotriene biosynthesis. *Eur J Med Res* 1996; 1; 369-70.
26. Ammon HPT, Safayhi H, Mack T, Sabieraj J. Mechanism of anti-inflammatory action of curcumine and Boswellic acids. *J Ethno* 1993; 38:113-19.
27. Sailer ER, Suberamanian LR, Rall B, Hoernlein RF, Ammon HPT et. al. Acetyl -II-Keto-β-Boswellic acid (AKBA): Structure requirements for binding and 5-lipoxygenase inhibitory activity. *Br J Pharma* 1996;117:615-18.
28. Sajayhi H, Rall B, Sailer ER and Ammon HPT; Inhibition by Boswellic acids of human leukocyte elastase *J Pharma Exp Ther* 1997; 281, 160-63.
29. Gupta I, Parihar A, Malhotra P, et al. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. *Eur J Med Res* 1997; 2, 37-43.
30. Gerhardt H, Seifert F, Buvari P, Vogelsang H, Repges R. Therapi des aktiven Morbus Crohn mit dem. Boswellia serrata. Extract H15 *Z. Gastroenterol* 2001; 39, 11-17.
31. Murphy RC, Hammarstrom S, Samuelsson B. Leukotrienes C<sub>4</sub>. A slow reacting substance from murine mastocytoma cells. *Proc. Natl Acad Sci USA* 1979; 76,4275-79.
32. Kellaway CH, Trethewie RE. The Liberation of a slow reacting smooth muscle stimulating substance of anaphylaxis. *J Exp Physiol* 1940;30:121-45.
33. Drazen JM, Austen KF. Leukotriene and airway responses. *Am Rev Resp Disease* 1987; 136: 985-98.
34. O, Byrne PM, Israel E, Drazen JM. Anti-leukotrienes in the treatment of asthma. *Ann Intern Med* 1997;127:472-80.
35. Spector SL. Alternative treatment in the patients with intractable asthma. *Curr Opin Pulm Med* 1997;3: 23-29.
36. Gupta I, Gupta V, Parihar A, et al. Effects of Boswellia serrata gum resin in patients with bronchial asthma. Results of a double blind placebo controlled 6 weeks clinical study. *Eur J Med Res* 1998; 3: 511-14.
37. Griffen M, Weiss JW, Leitch AG et al. Effects of leukotriene D<sub>4</sub> on the airway in asthma. *N Engl J Med* 1983; 308: 436-39.
38. Hui KP, Barmes NC. Lung function improvement in asthma with a cysteinyl leukotriene receptor antagonist. *Lancet* 1991; 337: 1062-63.
39. Placentini GL, Kalimer MA. The potential roles of leukotrienes in bronchial asthma. *Am Review Respiratory Disease* 1991; 143:546-99.
40. Nicholas Chanarin and Sebastian L Johnston Leukotrienes as a target in asthma therapy. *Drugs* 1994; 47(1): 12-24.
41. Feldberg W, Kellaway CH. Liberation of histamine and formation of lysolecithin like substances by cobra venom. *J Physiol (Cambridge England)* 1938; 94: 187-226.
42. Heidt RM et al. Boswellic acids exhibit cytotoxic effects on brain tumour cells independent from 5-lipoxygenase inhibitions. *Naumyn S Arch Pharmacol* 1997; 335(S) R15 Abstract 30.
43. Bogenrieter T et al. Analysis of pentacyclic triterpene-mediated anti proliferative effects on malignant melanoma cells. *Proc Am Assoc Cancer Res* 1997; 38. 216. Abstract 1458.
44. Boker DK, Winking M. Die Rolle Von. Boswellia Sauren in der Therapi maligner gliome. *Dtsch Arztebli* 1997; 94(18) A1197-A-1199.
45. Simmet Thomas, Weihrauch gegen Hirntumoren. *Deutsche Apotheker Zeitung* 1997; 137(3), 6.1.
46. Ford Hutchinson AW. Psoriasis. *Skin Pharmacol* 1993; 6: 292-95.
47. Ford Hutchinson AW. Leukotrine antagonists and inhibitors. In: Samuelson B et. al. (eds) Clinical Applications: Advances in Proster glandin, Thromboxane and leukotrienes research Vol 23, Raven Press Ltd. New York. 1995; 69-74.
48. Bockns NL, Roth JLA, Buckman E. Life history of non-specific colitis. Relations of prognosis of anatomical and clinical varieties. *Gastroenterologia* 1956; 86: 549-52.
49. Banks BM, Korentz BT, Zetzel L. The course of non-specific colitis. A review of 20 years experience Late results. *Gastroenterol* 1957; 32, 983-87.
50. Wild fever A. Effects of Boswellic acides extracted from a herbal medicine on the biosynthesis of leukotrienes and the course of experimental autoinnune (Disease)-Encephalomyelitis. *IAWA* 1998; 19: 415-27.
51. Knaus U, Wagner H. Effects of boswellic acid Boswellia serrata and other trioterpenic acids on the complement system (lupus). *Phytomed* 1996; 3: 77-81.